{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T21:39:41Z","timestamp":1792100381821,"version":"4.4.0"},"reference-count":83,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,3]],"date-time":"2023-01-03T00:00:00Z","timestamp":1672704000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007452","name":"Wu Jieping Medical Foundation","doi-asserted-by":"publisher","award":["320.6750.17398"],"award-info":[{"award-number":["320.6750.17398"]}],"id":[{"id":"10.13039\/100007452","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Translational Oncology"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.tranon.2023.101619","type":"journal-article","created":{"date-parts":[[2023,1,7]],"date-time":"2023-01-07T17:28:11Z","timestamp":1673112491000},"page":"101619","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["The Current status of steroid-refractory immune-checkpoint-inhibitor-related hepatotoxicity"],"prefix":"10.1016","volume":"28","author":[{"given":"Hui","family":"Xing","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cuihua","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2764-1142","authenticated-orcid":false,"given":"Hui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.tranon.2023.101619_bib0001","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/nri2326","article-title":"Inhibitory B7-family molecules in the tumor microenvironment","volume":"8","author":"Zou","year":"2008","journal-title":"Nat. Rev. Immunol."},{"issue":"2","key":"10.1016\/j.tranon.2023.101619_bib0002","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.tranon.2023.101619_bib0003","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1002\/ijc.30678","article-title":"Risk of hepatotoxicity in cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis of published data","volume":"141","author":"Wang","year":"2017","journal-title":"Int. J. Cancer"},{"issue":"6","key":"10.1016\/j.tranon.2023.101619_bib0004","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1016\/j.jhep.2018.08.014","article-title":"Incidence of grade 3-4 liver injury under immune checkpoints inhibitors: a retrospective study","volume":"69","author":"Parlati","year":"2018","journal-title":"J. Hepatol."},{"key":"10.1016\/j.tranon.2023.101619_bib0005","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.3389\/fphar.2019.01671","article-title":"Organ-specific immune-related adverse events associated with immune checkpoint inhibitor monotherapy versus combination therapy in cancer: a meta-analysis of randomized controlled trials","volume":"10","author":"Da","year":"2020","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.tranon.2023.101619_bib0006","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.650292","article-title":"Immune checkpoint inhibitor associated hepatotoxicity in primary liver cancer versus other cancers: a systematic review and meta-analysis","volume":"11","author":"Fu","year":"2021","journal-title":"Front. Oncol."},{"issue":"12","key":"10.1016\/j.tranon.2023.101619_bib0007","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis [published correction appears in JAMA Oncol. 2018 Dec 1;4(12):1792]","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.tranon.2023.101619_bib0008","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.ejca.2019.09.022","article-title":"Increased reporting of fatal hepatitis associated with immune checkpoint inhibitors","volume":"123","author":"Vozy","year":"2019","journal-title":"Eur. J. Cancer"},{"issue":"suppl_4","key":"10.1016\/j.tranon.2023.101619_bib0009","doi-asserted-by":"crossref","first-page":"iv119","DOI":"10.1093\/annonc\/mdx225","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up [published correction appears in Ann Oncol. 2018 Oct 1;29(Suppl 4):iv264-iv266]","volume":"28","author":"Haanen","year":"2017","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.tranon.2023.101619_bib0010","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s40425-017-0300-z","article-title":"Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group","volume":"5","author":"Puzanov","year":"2017","journal-title":"J. Immunother. Cancer"},{"issue":"17","key":"10.1016\/j.tranon.2023.101619_bib0011","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.tranon.2023.101619_bib0012","doi-asserted-by":"crossref","first-page":"6129","DOI":"10.1007\/s00520-020-05707-3","article-title":"Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of severe gastrointestinal and hepatic toxicities from checkpoint inhibitors","volume":"28","author":"Dougan","year":"2020","journal-title":"Support Care Cancer"},{"issue":"4","key":"10.1016\/j.tranon.2023.101619_bib0013","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1053\/j.gastro.2020.08.063","article-title":"AGA clinical practice update on diagnosis and management of immune checkpoint inhibitor colitis and hepatitis: expert review","volume":"160","author":"Dougan","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.tranon.2023.101619_bib0014","series-title":"Guidelines of Chinese Society of Clinical Oncology(CSCO)Management of Immune Checkpoint Inhibitor-Related Toxicity(2021)","year":"2021"},{"key":"10.1016\/j.tranon.2023.101619_bib0015","unstructured":"National Comprehensive Cancer Network\u00ae. NCCN-guidelines-Management of Immunotherapy-related Toxicities 2022 version1. Available at: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/immunotherapy.pdf. Accessed August 19, 2022."},{"issue":"4","key":"10.1016\/j.tranon.2023.101619_bib0016","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1055\/s-0038-1667358","article-title":"Liver toxicity with cancer checkpoint inhibitor therapy","volume":"38","author":"Nadeau","year":"2018","journal-title":"Semin. Liver Dis."},{"key":"10.1016\/j.tranon.2023.101619_bib0017","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.critrevonc.2018.09.019","article-title":"Liver toxicity in the era of immune checkpoint inhibitors: a practical approach","volume":"132","author":"Belli","year":"2018","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"3","key":"10.1016\/j.tranon.2023.101619_bib0018","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1080\/17425255.2019.1574744","article-title":"Hepatotoxicity induced by immune checkpoint inhibitors: a comprehensive review including current and alternative management strategies","volume":"15","author":"Jennings","year":"2019","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"issue":"8","key":"10.1016\/j.tranon.2023.101619_bib0019","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1111\/apt.15449","article-title":"Review article: immune checkpoint inhibitors and the liver, from therapeutic efficacy to side effects","volume":"50","author":"Lombardi","year":"2019","journal-title":"Aliment. Pharmacol. Ther."},{"issue":"2","key":"10.1016\/j.tranon.2023.101619_bib0020","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.jhep.2019.10.021","article-title":"Diagnosis and management of toxicities of immune checkpoint inhibitors in hepatocellular carcinoma","volume":"72","author":"Sangro","year":"2020","journal-title":"J. Hepatol."},{"issue":"1","key":"10.1016\/j.tranon.2023.101619_bib0021","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/hep.31227","article-title":"Hepatotoxicity from immune checkpoint inhibitors: a systematic review and management recommendation","volume":"72","author":"Peeraphatdit","year":"2020","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.tranon.2023.101619_bib0022","doi-asserted-by":"crossref","first-page":"101","DOI":"10.3390\/biomedicines9020101","article-title":"Checkpoint inhibitors and hepatotoxicity","volume":"9","author":"Malnick","year":"2021","journal-title":"Biomedicines"},{"issue":"2","key":"10.1016\/j.tranon.2023.101619_bib0023","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001322","article-title":"When steroids are not enough in immune-related hepatitis: current clinical challenges discussed on the basis of a case report","volume":"8","author":"Ziogas","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.tranon.2023.101619_bib0024","article-title":"Immune checkpoint inhibitor-related cholangiopathy: novel clinicopathological description of a multi-center cohort","author":"Berry","year":"2022","journal-title":"Liver Int."},{"issue":"1","key":"10.1016\/j.tranon.2023.101619_bib0025","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2021.1875639","article-title":"A multicenter characterization of hepatitis associated with immune checkpoint inhibitors","volume":"10","author":"Patrinely","year":"2021","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.tranon.2023.101619_bib0026","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.ejca.2020.02.041","article-title":"Characterization of risk factors and efficacy of medical management of immune-related hepatotoxicity in real-world patients with metastatic melanoma treated with immune checkpoint inhibitors","volume":"130","author":"Romanski","year":"2020","journal-title":"Eur. J. Cancer"},{"issue":"2","key":"10.1016\/j.tranon.2023.101619_bib0027","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1007\/s12072-021-10151-4","article-title":"Checkpoint inhibitor induced hepatitis and the relation with liver metastasis and outcome in advanced melanoma patients","volume":"15","author":"Biewenga","year":"2021","journal-title":"Hepatol. Int."},{"issue":"23","key":"10.1016\/j.tranon.2023.101619_bib0028","doi-asserted-by":"crossref","first-page":"5088","DOI":"10.1002\/cncr.33165","article-title":"Outcomes after resumption of immune checkpoint inhibitor therapy after high-grade immune-mediated hepatitis","volume":"126","author":"Li","year":"2020","journal-title":"Cancer"},{"issue":"8","key":"10.1016\/j.tranon.2023.101619_bib0029","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1097\/COC.0000000000000374","article-title":"Hepatotoxicity after immune checkpoint inhibitor therapy in melanoma: natural progression and management","volume":"41","author":"Huffman","year":"2018","journal-title":"Am. J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.tranon.2023.101619_bib0030","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1002\/hep.32215","article-title":"Effect of corticosteroid dosing on outcomes in high-grade immune checkpoint inhibitor hepatitis","volume":"75","author":"Li","year":"2022","journal-title":"Hepatology"},{"key":"10.1016\/j.tranon.2023.101619_bib0031","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/6391712","article-title":"Clinical features of liver injury induced by immune checkpoint inhibitors in Japanese patients","volume":"2019","author":"Imoto","year":"2019","journal-title":"Can. J. Gastroenterol. Hepatol."},{"issue":"5","key":"10.1016\/j.tranon.2023.101619_bib0032","doi-asserted-by":"crossref","first-page":"763","DOI":"10.3390\/healthcare10050763","article-title":"Clinical characteristics of ICI-related pancreatitis and cholangitis including radiographic and endoscopic findings","volume":"10","author":"Nakano","year":"2022","journal-title":"Healthcare (Basel)"},{"key":"10.1016\/j.tranon.2023.101619_bib0033","article-title":"Atezolizumab-induced Sclerosing Cholangitis in a patient with lung cancer: a case report","volume":"26","author":"Nabeshima","year":"2021","journal-title":"Cancer Treat. Res. Commun."},{"key":"10.1016\/j.tranon.2023.101619_bib0034","doi-asserted-by":"crossref","first-page":"17","DOI":"10.4254\/wjh.v6.i1.17","article-title":"Drug and herb induced liver injury: council for International Organizations of Medical Sciences scale for causality assessment","volume":"6","author":"Teschke","year":"2014","journal-title":"World J. Hepatol."},{"key":"10.1016\/j.tranon.2023.101619_bib0035","article-title":"Resolution of ipilimumab induced severe hepatotoxicity with triple immunosuppressants therapy","volume":"2015","author":"Ahmed","year":"2015","journal-title":"BMJ Case Rep."},{"key":"10.1016\/j.tranon.2023.101619_bib0036","doi-asserted-by":"crossref","first-page":"853","DOI":"10.3389\/fphar.2019.00853","article-title":"Roussel Uclaf causality assessment method for drug-induced liver injury: present and future","volume":"10","author":"Danan","year":"2019","journal-title":"Front. Pharmacol."},{"issue":"7","key":"10.1016\/j.tranon.2023.101619_bib0037","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1111\/apt.15413","article-title":"Liver injury is most commonly due to hepatic metastases rather than drug hepatotoxicity during pembrolizumab immunotherapy","volume":"50","author":"Tsung","year":"2019","journal-title":"Aliment. Pharmacol. Ther."},{"issue":"6","key":"10.1016\/j.tranon.2023.101619_bib0038","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/j.jhep.2018.01.033","article-title":"Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors","volume":"68","author":"De Martin","year":"2018","journal-title":"J. Hepatol."},{"issue":"9","key":"10.1016\/j.tranon.2023.101619_bib0039","doi-asserted-by":"crossref","first-page":"FSO614","DOI":"10.2144\/fsoa-2020-0056","article-title":"Steroid-refractory immune related hepatitis may hide viral re-activation","volume":"6","author":"Citarella","year":"2020","journal-title":"Future Sci. OA"},{"issue":"1","key":"10.1016\/j.tranon.2023.101619_bib0040","first-page":"27","article-title":"Liver biochemical flare with immune checkpoint therapy in metastatic Merkel cell carcinoma: a liver biopsy is always necessary","volume":"3","author":"Al-Rajhi","year":"2021","journal-title":"Hepatol. Forum"},{"issue":"6","key":"10.1016\/j.tranon.2023.101619_bib0041","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1007\/s00535-020-01677-9","article-title":"Real world data of liver injury induced by immune checkpoint inhibitors in Japanese patients with advanced malignancies","volume":"55","author":"Mizuno","year":"2020","journal-title":"J. Gastroenterol."},{"issue":"4","key":"10.1016\/j.tranon.2023.101619_bib0042","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2017-000268","article-title":"Severe steroid-resistant anti-PD1 T-cell checkpoint inhibitor-induced hepatotoxicity driven by biliary injury","volume":"2","author":"Doherty","year":"2017","journal-title":"ESMO Open"},{"issue":"9","key":"10.1016\/j.tranon.2023.101619_bib0043","doi-asserted-by":"crossref","first-page":"e237","DOI":"10.1200\/JCO.2010.32.2206","article-title":"Resolution of severe ipilimumab-induced hepatitis after antithymocyte globulin therapy","volume":"29","author":"Chmiel","year":"2011","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.tranon.2023.101619_bib0044","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s00262-017-2107-7","article-title":"Anti-PD-1-induced high-grade hepatitis associated with corticosteroid-resistant T cells: a case report","volume":"67","author":"McGuire","year":"2018","journal-title":"Cancer Immunol. Immunother."},{"issue":"1","key":"10.1016\/j.tranon.2023.101619_bib0045","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1186\/s13256-020-02541-3","article-title":"Ursodeoxycholic acid and bezafibrate were useful for steroid-refractory, immune-related hepatitis: a case report","volume":"14","author":"Onishi","year":"2020","journal-title":"J. Med. Case Rep."},{"issue":"17","key":"10.1016\/j.tranon.2023.101619_bib0046","doi-asserted-by":"crossref","first-page":"4415","DOI":"10.12998\/wjcc.v9.i17.4415","article-title":"Efficacy of artificial liver support system in severe immune-associated hepatitis caused by camrelizumab: a case report and review of the literature","volume":"9","author":"Tan","year":"2021","journal-title":"World J. Clin. Cases"},{"issue":"7","key":"10.1016\/j.tranon.2023.101619_bib0047","doi-asserted-by":"crossref","first-page":"585","DOI":"10.2217\/imt-2018-0187","article-title":"PD-L1 expressing granulomatous reaction as an on-target mechanism of steroid-refractory immune hepatotoxicity","volume":"11","author":"Black","year":"2019","journal-title":"Immunotherapy"},{"issue":"1","key":"10.1016\/j.tranon.2023.101619_bib0048","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.jhep.2021.02.008","article-title":"Activation and transcriptional profile of monocytes and CD8+ T cells are altered in checkpoint inhibitor-related hepatitis","volume":"75","author":"Gudd","year":"2021","journal-title":"J. Hepatol."},{"issue":"2","key":"10.1016\/j.tranon.2023.101619_bib0049","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s12328-022-01590-z","article-title":"Re-administration of nivolumab after immune checkpoint inhibitor-induced cholangitis: the first reported case","volume":"15","author":"Kataoka","year":"2022","journal-title":"Clin. J. Gastroenterol."},{"issue":"2","key":"10.1016\/j.tranon.2023.101619_bib0050","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1159\/000516199","article-title":"Intrahepatic bile duct injury as a hepatic immune-related adverse event after immune-checkpoint inhibitor treatment","volume":"15","author":"Murayama","year":"2021","journal-title":"Case Rep. Gastroenterol."},{"key":"10.1016\/j.tranon.2023.101619_bib0051","article-title":"A case of large-cell lung carcinoma successfully treated with pembrolizumab but complicated with cholangitis","volume":"31","author":"Ooi","year":"2020","journal-title":"Respir. Med. Case Rep."},{"key":"10.1016\/j.tranon.2023.101619_bib0052","doi-asserted-by":"crossref","first-page":"e1624","DOI":"10.1002\/cnr2.1624","article-title":"Mycophenolate mofetil for immune checkpoint inhibitor-related hepatotoxicity relapsing during dose reduction of corticosteroid: a report of two cases and literature review","author":"Ueno","year":"2022","journal-title":"Cancer Rep."},{"issue":"2","key":"10.1016\/j.tranon.2023.101619_bib0053","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/s12328-022-01593-w","article-title":"Pembrolizumab-related cholangitis with multiple fatal liver abscesses after endoscopic biliary drainage: a case report and review of the literature","volume":"15","author":"Hori","year":"2022","journal-title":"Clin. J. Gastroenterol."},{"issue":"1","key":"10.1016\/j.tranon.2023.101619_bib0054","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s12328-020-01287-1","article-title":"A case with life-threatening secondary sclerosing cholangitis caused by nivolumab","volume":"14","author":"Yoshikawa","year":"2021","journal-title":"Clin. J. Gastroenterol."},{"issue":"23","key":"10.1016\/j.tranon.2023.101619_bib0055","doi-asserted-by":"crossref","first-page":"e25774","DOI":"10.1097\/MD.0000000000025774","article-title":"A case report on severe nivolumab-induced adverse events similar to primary sclerosing cholangitis refractory to immunosuppressive therapy","volume":"100","author":"Hirasawa","year":"2021","journal-title":"Medicine (Baltimore)."},{"issue":"23","key":"10.1016\/j.tranon.2023.101619_bib0056","doi-asserted-by":"crossref","first-page":"3055","DOI":"10.2169\/internalmedicine.5216-20","article-title":"Infliximab was found to be effective for treating immunosuppressive drug-resistant hepatitis due to durvalumab","volume":"59","author":"Nakashima","year":"2020","journal-title":"Intern. Med."},{"issue":"6","key":"10.1016\/j.tranon.2023.101619_bib0057","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1007\/s12328-020-01178-5","article-title":"Pembrolizumab-induced sclerosing cholangitis in a lung adenocarcinoma patient with a remarkable response to chemotherapy: a case report","volume":"13","author":"Sato","year":"2020","journal-title":"Clin. J. Gastroenterol."},{"issue":"6","key":"10.1016\/j.tranon.2023.101619_bib0058","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1002\/hep.31396","article-title":"Severe refractory checkpoint inhibitor-related hepatitis reversed with anti-thymocyte globulin and n-acetylcysteine","volume":"72","author":"Motomura","year":"2020","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.tranon.2023.101619_bib0059","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1159\/000509953","article-title":"Pembrolizumab-induced delayed-onset hepatitis","volume":"14","author":"Kanaoka","year":"2020","journal-title":"Case Rep. Gastroenterol."},{"issue":"7","key":"10.1016\/j.tranon.2023.101619_bib0060","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1111\/1759-7714.13463","article-title":"Compromise or not? A case report of successful treatment of pembrolizumab-induced hepatitis in a patient with non-small cell lung cancer with low-dose methylprednisolone and bicyclol","volume":"11","author":"Liu","year":"2020","journal-title":"Thorac. Cancer"},{"issue":"2","key":"10.1016\/j.tranon.2023.101619_bib0061","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1159\/000507695","article-title":"Fatal cholestatic liver injury during treatment with pd1 immune checkpoint inhibitor for malignant melanoma: a case report","volume":"13","author":"Thorsteinsdottir","year":"2020","journal-title":"Case Rep. Oncol."},{"issue":"4","key":"10.1016\/j.tranon.2023.101619_bib0062","doi-asserted-by":"crossref","first-page":"omaa027","DOI":"10.1093\/omcr\/omaa027","article-title":"Mycophenolate mofetil as a successful treatment of corticosteroid-resistant immune checkpoint inhibitor-induced hepatitis","volume":"2020","author":"Nakano","year":"2020","journal-title":"Oxf. Med. Case Rep."},{"issue":"2","key":"10.1016\/j.tranon.2023.101619_bib0063","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1634\/theoncologist.2018-0162","article-title":"Workup and management of immune-mediated hepatobiliary pancreatic toxicities that develop during immune checkpoint inhibitor treatment","volume":"25","author":"Hsu","year":"2020","journal-title":"Oncologist"},{"key":"10.1016\/j.tranon.2023.101619_bib0064","article-title":"A case of simultaneous occurrence of hepatitis and pancreatitis during the combination immunochemotherapy for non-small cell lung carcinoma","volume":"31","author":"Tanaka","year":"2020","journal-title":"Respir. Med. Case Rep."},{"issue":"3","key":"10.1016\/j.tranon.2023.101619_bib0065","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.jhep.2018.10.020","article-title":"Acute liver failure due to immune-mediated hepatitis successfully managed with plasma exchange: new settings call for new treatment strategies?","volume":"70","author":"Riveiro-Barciela","year":"2019","journal-title":"J. Hepatol."},{"issue":"1","key":"10.1016\/j.tranon.2023.101619_bib0066","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.jhepr.2019.02.001","article-title":"Infliximab for the treatment of refractory immune-related hepatitis secondary to checkpoint inhibitors: a case report","volume":"1","author":"Corrigan","year":"2019","journal-title":"JHEP Rep."},{"key":"10.1016\/j.tranon.2023.101619_bib0067","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.ejca.2017.05.018","article-title":"Severe hepatitis under combined immunotherapy: resolution under corticosteroids plus anti-thymocyte immunoglobulins","volume":"81","author":"Sp\u00e4nkuch","year":"2017","journal-title":"Eur. J. Cancer"},{"issue":"3","key":"10.1016\/j.tranon.2023.101619_bib0068","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1684\/ejd.2017.2973","article-title":"Azathioprine combination therapy for steroid-refractory hepatic immune system-related adverse events","volume":"27","author":"Iwamoto","year":"2017","journal-title":"Eur. J. Dermatol."},{"issue":"2","key":"10.1016\/j.tranon.2023.101619_bib0069","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1093\/jjco\/hyw167","article-title":"Severe hepatitis arising from ipilimumab administration, following melanoma treatment with nivolumab","volume":"47","author":"Tanaka","year":"2017","journal-title":"Jpn. J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.tranon.2023.101619_bib0070","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/s41584-020-0374-8","article-title":"Mycophenolate mofetil, azathioprine and tacrolimus: mechanisms in rheumatology","volume":"16","author":"Broen","year":"2020","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.tranon.2023.101619_bib0071","series-title":"CELLCEPT (mycophenolate mofetil) Capsules, for Oral Use [Prescribing Information]","year":"2021"},{"issue":"2","key":"10.1016\/j.tranon.2023.101619_bib0072","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.cgh.2017.09.063","article-title":"Efficacy and safety of mycophenolate mofetil in patients with autoimmune hepatitis and suboptimal outcomes after standard therapy","volume":"16","author":"Roberts","year":"2018","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"9","key":"10.1016\/j.tranon.2023.101619_bib0073","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1080\/10428190802163321","article-title":"Mechanisms of action of antithymocyte globulin: old dogs with new tricks!","volume":"49","author":"Mohty","year":"2008","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.tranon.2023.101619_bib0074","series-title":"THYMOGLOBULIN (Anti-Thymocyte Globulin [Rabbit]) for Intravenous Use [Prescribing Information]","year":"2017"},{"key":"10.1016\/j.tranon.2023.101619_bib0075","series-title":"Atgam(Lymphocyte Immune Globulin, Anti-Thymocyte Globulin [Equine] Sterile Solution) for Intravenous Use [Prescribing Information]","year":"2005"},{"key":"10.1016\/j.tranon.2023.101619_bib0076","series-title":"PROGRAF (Tacrolimus) Capsules, for Oral Use [Prescribing Information]","year":"2021"},{"key":"10.1016\/j.tranon.2023.101619_bib0077","series-title":"NEORAL (Cyclosporine Capsules, USP) for Oral Use [Prescribing Information]","year":"2015"},{"issue":"5","key":"10.1016\/j.tranon.2023.101619_bib0078","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1177\/1078155218793709","article-title":"Tacrolimus for the treatment of immune-related adverse effects refractory to systemic steroids and anti-tumor necrosis factor \u03b1 therapy","volume":"25","author":"Beardslee","year":"2019","journal-title":"J. Oncol. Pharm. Pract."},{"key":"10.1016\/j.tranon.2023.101619_bib0079","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.3389\/fonc.2020.01760","article-title":"Case report: successful treatment of steroid-refractory immune checkpoint inhibitor-related pure red cell aplasia with cyclosporin","volume":"10","author":"G\u00e9rard","year":"2020","journal-title":"Front. Oncol."},{"issue":"3","key":"10.1016\/j.tranon.2023.101619_bib0080","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.jhep.2016.11.015","article-title":"Managing immune checkpoint-inhibitor-induced severe autoimmune-like hepatitis by liver-directed topical steroids","volume":"66","author":"Ziemer","year":"2017","journal-title":"J. Hepatol."},{"issue":"2","key":"10.1016\/j.tranon.2023.101619_bib0081","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.jtho.2020.09.007","article-title":"Personalized cytokine-directed therapy with tocilizumab for refractory immune checkpoint inhibitor-related cholangiohepatitis","volume":"16","author":"Moi","year":"2021","journal-title":"J. Thorac. Oncol."},{"issue":"1","key":"10.1016\/j.tranon.2023.101619_bib0082","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.jhepr.2019.02.001","article-title":"Infliximab for the treatment of refractory immune-related hepatitis secondary to checkpoint inhibitors: a case report[J]","volume":"1","author":"Corrigan","year":"2019","journal-title":"JHEP Rep."},{"issue":"23","key":"10.1016\/j.tranon.2023.101619_bib0083","doi-asserted-by":"crossref","first-page":"3055","DOI":"10.2169\/internalmedicine.5216-20","article-title":"Infliximab was found to be effective for treating immunosuppressive drug-resistant hepatitis due to durvalumab[J]","volume":"59","author":"Nakashima","year":"2020","journal-title":"Intern. Med."}],"container-title":["Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936523323000049?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936523323000049?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,8]],"date-time":"2024-09-08T17:34:53Z","timestamp":1725816893000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1936523323000049"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":83,"alternative-id":["S1936523323000049"],"URL":"https:\/\/doi.org\/10.1016\/j.tranon.2023.101619","relation":{},"ISSN":["1936-5233"],"issn-type":[{"value":"1936-5233","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Current status of steroid-refractory immune-checkpoint-inhibitor-related hepatotoxicity","name":"articletitle","label":"Article Title"},{"value":"Translational Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tranon.2023.101619","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101619"}}